AUTOIMMUNE THROMBOCYTOPENIA PURPURA - PATHOGENESIS, DIAGNOSIS AND MANAGEMENT

Citation
Ae. Ahmed et al., AUTOIMMUNE THROMBOCYTOPENIA PURPURA - PATHOGENESIS, DIAGNOSIS AND MANAGEMENT, CLINICAL IMMUNOTHERAPEUTICS, 1(5), 1994, pp. 348-357
Citations number
110
Categorie Soggetti
Immunology,"Pharmacology & Pharmacy
Journal title
ISSN journal
11727039
Volume
1
Issue
5
Year of publication
1994
Pages
348 - 357
Database
ISI
SICI code
1172-7039(1994)1:5<348:ATP-PD>2.0.ZU;2-7
Abstract
Autoimmune thrombocytopenia purpura (AITP) is a common haematological disorder caused by antiplatelet autoantibodies that lead to increased clearance of platelets by the reticuloendothelial system. Patients wit h AITP have low platelet counts and a bleeding tendency affecting the skin and mucosa. AITP can be classified into 2 main clinical syndromes : (a) idiopathic (primary or essential) thrombocytopenia (ITP) and (b) secondary AITP. Secondary AITP occurs in conjunction with a primary ( usually autoimmune or malignant) disorder, and accounts for the majori ty of cases of AITP. ITP has an unknown aetiology, and diagnosis is ma de by exclusion of secondary AITP. Laboratory diagnosis of AITP relies on detection of platelet-associated immunoglobulin or on the demonstr ation of platelet autoantibodies that react with specific target antig ens on the platelet surface. Treatment of AITP involves therapy with c orticosteroids, followed if necessary by splenectomy. The use of high- dosage intravenous immunoglobulin G may improve the response to cortic osteroids.